AstraZeneca (NYSE:AZN) and collaboration partner Daiichi Sankyo (OTCPK:DSKYF) announce positive data
from a Phase 2 clinical trial, DESTINY-Gastric01, evaluating Enhertu
(fam-trastuzumab deruxtecan-nxki) in patients with HER2-positive
unresectable/metastatic gastric or gastroesophageal junction
adenocarcinoma who progressed after two or more prior lines of therapy,
including chemo and trastuzumab.
The objective response rate (ORR) was 42.9%
compared to 12.5% for chemo (paclitgaxel or irinotecan), including 10
complete responders, with 41% less risk of death. The disease control
rate (responders + stable cancer) was 85.7% in the Enhertu group
compared to 62.5% in the chemo group. Median duration of response was
11.3 months and 3.9 months, respectively.
Median overall survival (OS) was 12.5 months versus 8.4 months in the chemo arm.
Enhertu is an HER2-directed antibody and
topoisomerase inhibitor conjugate currently approved for the treatment
of adult patients with unresectable or metastatic HER2-positive breast
cancer who have received two or more prior anti-HER2-based regimens in
the metastatic setting.
AZN up 4% premarket.
#ASCO20
https://seekingalpha.com/news/3578660-astrazeneca-antibody-drug-conjugate-shows-positive-effect-in-gastric-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.